πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

3,067 results for β€œHospital” Clear

  1. Linperlisib combination with obinutuzumab

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 2 small molecule active

    1 trial

  2. Liposomal irinotecan

    The First People's Hospital of Lianyungang

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  3. Liposorber LA-15 System

    Hospital Authority, Hong Kong

    Cholesterol Embolism

    phase 2 other active

    1 trial

  4. Liposuction

    The First People's Hospital of Lianyungang

    Anterior Cruciate Ligament Partial Rupture

    phase 2 other active

    1 trial

  5. Lithium Carbonate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  6. Loratadine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rhinitis, Allergic, Perennial

    phase 2 small molecule completed

    1 trial

  7. Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab completed

    1 trial

  8. Luspatercept

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HSCT

    phase 2 small molecule active

    1 trial

  9. Luspatercept combined with low-dose thalidomide

    The First People's Hospital of Lianyungang

    Transfusion-dependent Ξ²-thalassemia Patients

    phase 2 small molecule active

    1 trial

  10. Lusutrombopag Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Idiopathic Thrombocytopenic Purpura

    phase 2 small molecule completed

    1 trial

  11. Luveris

    Peking University Third Hospital

    Infertility

    phase 2 small molecule active

    1 trial

  12. Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Faslodex 250 mg solution for injection., Lynparza 150 mg film-coated tablets, Zoladex 3.6 mg Implant

    Ningbo Cancer Hospital

    ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.

    phase 2 small molecule active

    1 trial

  13. MB07133

    The First People's Hospital of Lianyungang

    Safety Issues

    phase 2 small molecule active

    1 trial

  14. MIE

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 other active

    1 trial

  15. MK-1045

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  16. MLC901

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  17. MOGAMULIZUMAB

    Ningbo Cancer Hospital

    Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a type of white blood cells) that primarily involve the skin, Cutaneous T-cell lymphoma (Mycosis Fungoides (MF)) and SΓ©zary Syndrome (SS))

    phase 2 small molecule active

    1 trial

  18. MRG003 combined with Dalpicicilip

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  19. MRG003 combined with Pucotenlimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  20. MSC

    The Children's Hospital of Zhejiang University School of Medicine

    BPD - Bronchopulmonary Dysplasia

    phase 2 small molecule active

    1 trial

  21. MSC and PRP

    Hospital Authority, Hong Kong

    Type 1 Diabetes Mellitus

    phase 2 mab active

    1 trial

  22. Marine active

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    "Hyperuricemia,Anserine"

    phase 2 small molecule active

    1 trial

  23. Medical Collagen Membrane with MSC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Wounds

    phase 2 other active

    1 trial

  24. Mekinist 2 mg film-coated tablets, Hydroxychloroquine sulfate Accord 200mg film-coated tablets, Mekinist 0.5 mg film-coated tablets

    Ningbo Cancer Hospital

    Metastatic refractory Pancreatic Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources